Status:
COMPLETED
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Lead Sponsor:
Novartis
Conditions:
Parkinson Disease
Dyskinesias
Eligibility:
All Genders
30-80 years
Phase:
PHASE2
Brief Summary
This phase IIb study is designed to determine the safe and efficacious dose or dose range of AFQ056 for the treatment of patients with moderate to severe Parkinson's disease with L-Dopa induced dyskin...
Eligibility Criteria
Inclusion
- Outpatients with Parkinson's disease (PD), treated with L-Dopa, experiencing dyskinesias for at least three months
Exclusion
- Surgical treatment for PD
- Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated)
- Advanced, severe or unstable disease (other than PD) that may interfere with the study outcome evaluations
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00986414
Start Date
September 1 2009
Last Update
February 23 2017
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Gosford, Australia, 2250
2
Novartis Investigative Site
Heidelberg, Australia
3
Novartis Investigative Site
Melbourne, Australia, 3050
4
Novartis Investigative Site
Parkville, Australia, 3181